{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:17:45Z","timestamp":1794244665221,"version":"4.9.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.schres.2023.09.019","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T19:18:26Z","timestamp":1694891906000},"page":"88-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["A 12-month audit of clozapine associated myocarditis in a South Australian Local Health Network: The importance of screening and personalised titration"],"prefix":"10.1016","volume":"268","author":[{"given":"Olivia","family":"Carswell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.schres.2023.09.019_bb0005","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2020.72","article-title":"Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: a retrospective 6-month mirror-image study","volume":"63","author":"Bioque","year":"2020","journal-title":"Eur. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.09.019_bb0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/1039856214533395","article-title":"A state-wide quality improvement system utilising nurse-led clinics for clozapine management","volume":"22","author":"Clark","year":"2014","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.schres.2023.09.019_bb0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2017.03.045","article-title":"Elevated clozapine levels associated with infection: a systematic review","volume":"192","author":"Clark","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.09.019_bb0020","article-title":"Dotting the I\u2019s and crossing the T\u2019s: a South Australian perspective on variability in troponin thresholds for myocarditis risk in clozapine treatment","author":"Clark","year":"2023","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.schres.2023.09.019_bb0025","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4088\/JCP.11r06977","article-title":"Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy","volume":"73","author":"Cohen","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.09.019_bb0030","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.schres.2018.05.044","article-title":"Is the higher incidence of clozapine induced myocarditis in Australia due to awareness and monitoring?","volume":"201","author":"Dawson","year":"2018","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2023.09.019_bb0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.rpsm.2021.07.004","article-title":"Clozapine-associated myocarditis in the World Health Organization\u2019s pharmacovigilance database: focus on reports from various countries","volume":"15","author":"De Las Cuevas","year":"2022","journal-title":"Rev. Psiquiatr. Salud. Ment. (Engl Ed)"},{"issue":"3","key":"10.1016\/j.schres.2023.09.019_bb0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.24869\/psyd.2022.411","article-title":"Reflections on the complex history of the concept of clozapine-induced inflammation during titration","volume":"34","author":"de Leon","year":"2022","journal-title":"Psychiatr. Danub."},{"issue":"3","key":"10.1016\/j.schres.2023.09.019_bb0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.30773\/pi.2022.0293","article-title":"Reflections on the lack of consideration of ethnic ancestry to stratify clozapine dosing","volume":"20","author":"de Leon","year":"2023","journal-title":"Psychiatry Investig."},{"issue":"1","key":"10.1016\/j.schres.2023.09.019_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/IJPSYM.IJPSYM_379_19","article-title":"Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview","volume":"42","author":"de Leon","year":"2020","journal-title":"Indian J. Psychol. Med."},{"issue":"1","key":"10.1016\/j.schres.2023.09.019_bb0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.psym.2019.08.008","article-title":"Rapid titration and decreased clozapine clearance may help explain five cases of clozapine-induced myocarditis in a New York hospital","volume":"61","author":"de Leon","year":"2020","journal-title":"Psychosomatics"},{"issue":"3","key":"10.1016\/j.schres.2023.09.019_bb0060","article-title":"An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine","volume":"35","author":"de Leon","year":"2022","journal-title":"Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2023.09.019_bb0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","volume":"55","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.09.019_bb0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JCP.0000000000001678","article-title":"Escaping the long shadow cast by agranulocytosis: reflections on clozapine pharmacovigilance focused on the United Kingdom","volume":"43","author":"de Leon","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2023.09.019_bb0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2007-1004591","article-title":"Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables","volume":"41","author":"Diaz","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.09.019_bb0080","series-title":"Clozaril\u00ae Patient Monitoring SystemTM Protocol","year":"2019"},{"issue":"4","key":"10.1016\/j.schres.2023.09.019_bb0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.rpsm.2021.10.003","article-title":"Valproate, obesity and other causes of clozapine poor metabolism in the context of rapid titration may explain clozapine-induced myocarditis: a re-analysis of a Turkish case series","volume":"15","author":"Ertugrul","year":"2022","journal-title":"Rev. Psiquiatr. Salud. Ment. (Engl Ed)"},{"issue":"6","key":"10.1016\/j.schres.2023.09.019_bb0090","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00004714-200212000-00013","article-title":"Clozapine and oral contraceptives: a possible drug interaction","volume":"22","author":"Gabbay","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2023.09.019_bb0095","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/JCP.0000000000001358","article-title":"Clozapine-associated myocarditis: a protocol for monitoring upon clozapine initiation and recommendations for how to conduct a clozapine rechallenge","volume":"41","author":"Griffin","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.09.019_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.06.003","article-title":"Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects: a retrospective chart review of seven hospitals","author":"Kikuchi","year":"2023","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2023.09.019_bb0115","first-page":"29","article-title":"Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases","volume":"24","author":"Koenig","year":"2022","journal-title":"Neuropsychopharmacol. Hung."},{"issue":"3","key":"10.1016\/j.schres.2023.09.019_bb0120","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/JCP.0000000000001193","article-title":"Implementation and outcomes of a clozapine-associated myocarditis screening program in a region of South Australia-lessons learned","volume":"40","author":"Nachmani Major","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.09.019_bb0100","series-title":"Guideline for the Use of Clozapine [EnglishVersion] (2009), Netherlands","year":"2013"},{"issue":"6","key":"10.1016\/j.schres.2023.09.019_bb0125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1192\/bjp.2023.27","article-title":"Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis","volume":"222","author":"Northwood","year":"2023","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.09.019_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.112491","article-title":"Clozapine and cardiotoxicity - a guide for psychiatrists written by cardiologists","volume":"282","author":"Patel","year":"2019","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2023.09.019_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.114247","article-title":"Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: a systematic case review","volume":"305","author":"Richardson","year":"2021","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.schres.2023.09.019_bb0140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/acps.12827","article-title":"Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study","volume":"137","author":"Rohde","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"issue":"6","key":"10.1016\/j.schres.2023.09.019_bb0145","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/00048674.2011.572852","article-title":"A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls","volume":"45","author":"Ronaldson","year":"2011","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2023.09.019_bb0150","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/0004867411433970","article-title":"Continuation of clozapine following mild myocarditis","volume":"46","author":"Ronaldson","year":"2012","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2023.09.019_bb0155","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.schres.2012.08.018","article-title":"Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study","volume":"141","author":"Ronaldson","year":"2012","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2023.09.019_bb0160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2217\/pgs-2020-0015","article-title":"Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?","volume":"21","author":"Ruan","year":"2020","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.schres.2023.09.019_bb0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000506355","article-title":"Around 3% of 1,300 levels were elevated during infections in a retrospective review of 131 Beijing hospital in-patients with more than 24,000 days of clozapine treatment","volume":"89","author":"Ruan","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.schres.2023.09.019_bb0105","series-title":"Clozapine Management Clinical Guideline Version 2.0","year":"2022"},{"issue":"3","key":"10.1016\/j.schres.2023.09.019_bb0170","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/JCP.0000000000001202","article-title":"Adding oral contraceptives to clozapine may require halving the clozapine dose: a new case and a literature review","volume":"40","author":"Schoretsanitis","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2023.09.019_bb0175","first-page":"153","article-title":"Should we routinely add CRP to clozapine titrations? - learning from three cases","volume":"24","author":"Shelton","year":"2022","journal-title":"Neuropsychopharmacol. Hung."},{"issue":"7","key":"10.1016\/j.schres.2023.09.019_bb0180","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/0706743719892709","article-title":"Protocol for clozapine rechallenge in a case of clozapine-induced myocarditis","volume":"65","author":"Shivakumar","year":"2020","journal-title":"Can. J. Psychiatr."},{"issue":"5","key":"10.1016\/j.schres.2023.09.019_bb0185","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1517\/17425255.2014.885504","article-title":"Clinically relevant interactions between newer antidepressants and second-generation antipsychotics","volume":"10","author":"Spina","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.schres.2023.09.019_bb0190","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","article-title":"Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics","volume":"12","author":"Spina","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"5","key":"10.1016\/j.schres.2023.09.019_bb0195","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/acps.13398","article-title":"Risk factors for clozapine-induced myocarditis and cardiomyopathy: a systematic review and meta-analysis","volume":"145","author":"Vickers","year":"2022","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2023.09.019_bb0200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.9740\/mhc.2016.01.021","article-title":"A review of pharmacokinetic and pharmacodynamic interactions with antipsychotics","volume":"6","author":"Wijesinghe","year":"2016","journal-title":"Mental Health Clin."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423003298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423003298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T10:25:17Z","timestamp":1718101517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423003298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":40,"alternative-id":["S0920996423003298"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.09.019","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 12-month audit of clozapine associated myocarditis in a South Australian Local Health Network: The importance of screening and personalised titration","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}